UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
 
Date of Report: December 15, 2009
(Date of earliest event reported)
 
 
Oragenics, Inc
(Exact name of registrant as specified in its charter)
 
 
FL
  
001-38122
  
59-3410522
(State or other jurisdiction
of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification Number)
 
13700 Progress Blvd
  
32615
(Address of principal executive offices)
  
(Zip Code)
 
386-418-4018
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

ITEM 8.01 OTHER EVENTS

           Oragenics, Inc. issued a Press Release on December 15, 2009 regarding the Company’s progress with it’s probiotic oral care product EvoraPlus™.  The press release of December 15th is attached hereto as Exhibit 99.1 and is incorporated by reference.

ITEM 9.01 FINANCIAL INFORMATION AND EXHIBITS

(c) Exhibits.

Number
  
Description
99.1
  
Press Release on December 15, 2009
 
 
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 15th day of December, 2009.

 
ORAGENICS, INC.
(Registrant)
   
 
BY:
/s/ David Hirsch
 
   
David Hirsch
President and Chief Executive Officer
 
 
2